31 October 2025NewsAmericasJohn Cox at Barnes & Thornburg

Is Hatch-Waxman litigation for orphan drugs working?

Rising patent litigation over rare disease treatments highlights the success of the Hatch-Waxman and Orphan Drug Acts, says John Cox at Barnes & Thornburg.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
21 May 2026   European officials have again sided with Glenmark, concluding that the 3D mark for Boehringer’s HandiHaler device is ineligible for registration.
Americas
20 May 2026   The firm brings in a former VP at a biotech company, with biologics experience across antibodies, antibody drug-conjugates, peptides and gene and cell therapies.
Americas
19 May 2026   In the firm’s second IP conflict dispute in a year, a healthcare tech company claims Kirkland lawyers "committed the cardinal sin of trying to represent the conflicting interests of opposing parties".